

Gestational weight gain and dietary energy, iron, and choline intake predict severity of fetal alcohol growth restriction in a prospective birth cohort

R Colin Carter,¹ Marjanne Senekal,² Christopher P Duggan,³ Neil C Dodge,⁴ Ernesta M Meintjes,² Christopher D Molteno,^{3,5,6} Joseph L Jacobson,^{2,4} and Sandra W Jacobson^{2,4,6}

¹Institute of Human Nutrition and Departments of Emergency Medicine and Pediatrics, Columbia University Vagelos College of Physicians and Surgeons and NYP Morgan Stanley Children's Hospital, New York, NY, USA; ²Department of Human Biology, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa; ³Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA, USA; ⁴Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA; ⁵Departments of Nutrition and Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA; and ⁶Department of Psychiatry and Mental Health, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa

ABSTRACT

Background: Animal models have demonstrated that maternal nutrition can alter fetal vulnerability to prenatal alcohol exposure (PAE). Few human studies have examined the role of nutrition in fetal alcohol spectrum disorders (FASD).

Objectives: Our objectives were to examine whether fetal vulnerability to PAE-related growth restriction is modified by: 1) rate of gestational weight gain; or prenatal dietary intakes of 2) energy, 3) iron, or 4) choline.

Methods: In a prospective longitudinal birth cohort in Cape Town, South Africa, 118 heavy-drinking and 71 abstaining/lightdrinking pregnant women were weighed and interviewed regarding demographics, alcohol, cigarette/other drug use, and diet at prenatal visits. Infant length, weight, and head circumference were measured at 2 wk and 12 mo postpartum.

Results: Heavy-drinking mothers reported a binge pattern of drinking [Mean = 129 mL (~7.2 drinks)/occasion on 1.3 d/wk). Rate of gestational weight gain and average daily dietary energy, iron, and choline intakes were similar between heavy-drinking women and controls. In regression models adjusting for maternal age, socioeconomic status, cigarette use, and weeks gestation at delivery, PAE [ounces (30 mL) absolute alcohol per day] was related to smaller 2-wk length and head circumference and 12-mo length, weight, and head circumference *z*-scores ($\beta = -0.43$ to -0.67; all *P* values <0.05). In stratified analyses for each maternal nutritional measure (inadequate compared with adequate weight gain; tertiles for dietary energy, iron, and choline intakes), PAE-related growth restriction was more severe in women with poorer nutrition, with effect modification seen by weight gain, energy, iron, and/or choline for several anthropometric outcomes.

from nutritional interventions. *Am J Clin Nutr* 2022;116:460–469.

Keywords: fetal alcohol syndrome (FAS), fetal alcohol spectrum disorders (FASD), prenatal alcohol exposure (PAE), dietary energy intake, gestational weight gain, iron deficiency, choline, intrauterine growth restriction, postnatal growth restriction, fetal alcohol growth restriction

Introduction

Fetal alcohol spectrum disorders (FASD) are manifest by growth restriction and a broad range of cognitive and behavioral deficits. FASD comprise the most common preventable cause of neurodevelopmental disabilities worldwide, with prevalence estimates of 1.1–5.0% in the United States and Western Europe

Supplemental Figure 1 and Supplemental Tables 1–3 are available from the "Supplementary data" link in the online posting of the article and from the same link in the online table of contents at https://academic.oup.com/ajcn/.

460 *Am J Clin Nutr* 2022;116:460–469. Printed in USA. © The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Conclusions: Gestational weight gain and dietary intakes of energy, choline, and iron appeared to modify fetal vulnerability to PAE-related growth restriction. These findings suggest a need for screening programs for pregnant women at higher risk of having a child with FASD to identify alcohol-using women who could benefit

Supported by the NIH/National Institute on Alcohol Abuse and Alcoholism (R01AA016781, R21AA022203, K23AA020516; R01AA027916); the NIH/National Institute of Diabetes and Digestive and Kidney Diseases (K24DK104676; P30DK040561); and the Lycaki-Young Fund (State of Michigan).

CPD is an Editor on *The American Journal of Clinical Nutrition* and played no role in the Journal's evaluation of the manuscript.

Address correspondence to RCC (e-mail: rcc2142@cumc.columbia.edu).

Abbreviations used: AA, absolute alcohol; BAC, blood alcohol concentration; BSF, biceps skinfold thickness; FAS, fetal alcohol syndrome; FASD, fetal alcohol spectrum disorders; MUAC, midupper arm circumference; PAE, prenatal alcohol exposure; TSF, triceps skinfold thickness.

Received January 5, 2022. Accepted for publication April 11, 2022.

First published online April 19, 2022; doi: https://doi.org/10.1093/ajcn/nqac101.

(1) and 13.6–20.9% in South Africa (2). Fetal alcohol-related growth restriction is characterized by reductions in length, weight, and head circumference at birth that can persist through adulthood (3–10). We have demonstrated that a child's growth trajectory provides a biological indicator of the severity of FASD-related neurocognitive deficits, with the most affected children exhibiting both fetal and postnatal growth restriction (11).

It has been widely postulated that the nutritional status of women who drink alcohol during pregnancy can affect the severity of alcohol's teratogenic effects, but few human studies have examined the role of maternal nutrition in FASD. In rat models, protein and food restriction have been shown to exacerbate prenatal alcohol exposure (PAE)-related skeletal abnormalities (12) and fetal growth restriction (13). In a prospective longitudinal birth cohort in Detroit, United States (recruited 1986-1989), we found that PAE-related growth restriction through adulthood was markedly more severe in children born to mothers with prepregnancy weight below the cohort median (4). PAE has been associated with alterations in maternal and fetal iron bioavailability and utilization in rats that exacerbate PAE-related growth and neurobehavioral deficits and are ameliorated by maternal iron supplementation (14–16). We have found similar alterations in maternal and infant iron homeostasis in 2 prospective longitudinal birth cohorts in Cape Town, South Africa (one recruited from 1999 to 2001; the other from 2011 to 2015) (3, 17, 18). Animal models and 3 human trials have demonstrated protective effects of the methyl donor nutrient choline on PAE-related growth restriction and/or a range of neurobehavioral deficits (19-27).

In our more recent prospective South African birth cohort (28), we found that diet and body composition were similar between heavy-drinking pregnant women and abstainers/light-drinkers from the same community (29). However, nutrition was very poor in both groups across several dietary and anthropometric measures. In this article we examine the hypothesis that fetal vulnerability to PAE-related growth restriction can be modified by 4 elements of maternal nutrition: 1) rate of gestational weight gain; and dietary intakes of 2) energy (i.e., calories), 3) iron, and 4) choline.

Methods

Sample

Women were recruited from 2 antenatal clinics in Cape Town, South Africa, from 2011 to 2015 to take part in a prospective, longitudinal cohort study examining developmental effects of PAE (28, 29). The analysis plan and primary maternal nutritional measures and growth outcomes examined here comprise planned secondary analyses and were chosen prior to study initiation; sample size was chosen based on the primary outcome in the parent study, eyeblink conditioning (data not yet published). See Supplemental Figure 1 for recruitment and retention flow diagram. In timeline follow-back interviews (30, 31), any woman averaging \geq 1.0 oz (30 mL) absolute alcohol (AA)/day (~1.67 standard drinks) or reporting binge drinking [\geq 2.0 oz (60 mL) AA/drinking occasion] was invited to participate. Women who abstained or drank only minimally (no binge episodes) were recruited as controls. Maternal exclusion criteria at recruitment were age <18 y, HIV infection, multiple gestation pregnancy, and chronic medical conditions requiring pharmacological treatment. Infants meeting the following criteria (chosen prior to study initiation) were excluded from follow-up due to the potential negative effects of these conditions on growth and development: chromosomal anomalies (none), seizures (none), neural tube defects (none), very low birthweight (<1500 g) obtained from medical records (1 exposed, 2 controls), and extreme prematurity (<32 weeks gestation; 3 controls). The final sample included 118 exposed infants and 71 controls. Consents and interviews were conducted in the mother's preferred language (Afrikaans or English). Approval was obtained from the ethics committees at Wayne State University, University of Cape Town Faculty of Health Sciences, and Columbia University Medical Center. At each study visit, all women reporting alcohol or drug use were informed by our staff about the risks of prenatal alcohol and drug use, encouraged to stop or reduce their alcohol/drug use, and offered a referral to a substance use counseling/intervention program (South African National Council on Alcoholism and Drug Dependence).

Ascertainment of maternal alcohol, cigarette smoking, and drug use

In timeline follow-back interviews (30, 31) at recruitment and 4 and 12 weeks thereafter, women were asked about their alcohol use on a day-by-day basis during the previous 2 weeks, with recall linked to specific daily activities, as well as cigarette smoking and other drug use [cocaine, methamphetamine, opiates, methaqualone, and marijuana; validated by urine ELISA drug testing (32)]. At the recruitment visit, women were asked if there were weeks since conception when they drank smaller or greater quantities and were asked to report drinking for those weeks as well. At the 4- and 12-week visits, women were asked if there were any weeks since their last visit when they drank smaller or greater quantities and were asked to report drinking for those weeks as well. Summary alcohol measures were constructed using data from the 3 prenatal timeline follow-back interviews across pregnancy: ounces AA per day, ounces AA per drinking occasion, and frequency of drinking (1 oz = 30 mL) (33). The predictive validity of this timeline follow-back interview method is supported by consistent findings in 3 longitudinal cohorts in Detroit and Cape Town (4, 11, 30, 34) and validation studies using meconium alcohol biomarkers (35-37). Women who delivered before the 4- or 12-week study visit did not complete those visits; heavy-drinking women and controls did not differ in number of visits (Mean = 2.6 compared with 2.5, respectively; P = 0.110).

Maternal nutritional measures

Dietary interviews and weight measurements were conducted at each prenatal study visit by trained staff blinded to the mother's alcohol and drug use. Second/third-trimester rate of maternal gestational weight gain, which is generally stable over the second and third trimesters, was calculated as the average change in weight between study visits, divided by the number of weeks between visits (29). Because prepregnancy BMI was not known for any woman, the single inadequate gestational weight gain cutoff for second and third trimesters (<0.42 kg/week) was used (38). Average daily energy and iron intakes were calculated from multipass 24-h dietary recall interviews processed with FoodFinder3 (South African Medical Research Council) (29). Because FoodFinder3 does not include choline, average daily choline intake was calculated as the mean of values from a quantitative, choline-indicated FFQ developed and validated for this community (39). Given the propensity of 24-h recall interviews to overestimate the prevalence of values at upper and lower extremes, nutrient intake values were adjusted using the Nutrition Research Council method, which transforms outcome distributions to more closely match those of the general population while preserving cohort means (40). Dietary energy adequacy was calculated as the ratio of a woman's average daily energy intake to her estimated energy requirement, calculated based on her age, height, weight, activity level, and weeks gestation (29, 41, 42).

Infant anthropometry outcomes

Using standard WHO protocols, trained research staff blinded to maternal alcohol and drug use measured infant length, weight, and head circumference at 2 weeks and 12 months postpartum, and midupper arm circumference (MUAC) and triceps and biceps skinfold thickness (TSF and BSF, respectively) at 12 months (interexaminer reliability = 0.90-1.00) (43). WHO age/sex-specific anthropometric *z*-scores (43) were calculated for all but BSF (for which *z*-scores are unavailable) as the primary outcomes. Two-week measures were considered a proxy for birth size as a measure of fetal growth; this timepoint was chosen to avoid the impact of any early breastfeeding difficulties.

Demographics and other covariates

Mothers were interviewed regarding demographic background, including age, gravidity, education, and socioeconomic status. Weeks gestation at delivery was determined by early pregnancy ultrasound, if available, or last menstrual period. At 6.5 months postpartum, mothers were interviewed regarding number of weeks the infant was breastfed and if/when the infant was given formula.

Statistical analyses

All statistical analyses were 2-sided, using SPSS (v.24; IBM). All variables were examined for normality of distribution; AA per day was log-transformed due to skewness (>3.0). Missing data were treated with list-wise deletion. (Supplemental Table 1 compares key demographic, exposure, and prenatal nutritional measures between those with and without gestational weight gain and infant outcome measure data, which were all very similar.) The following covariates, which were found to be related to fetal alcohol growth restriction in prior studies (3, 4), were included as potential confounders in multivariable models: maternal age, prenatal cigarettes per day, socioeconomic status, and weeks gestation at delivery. (See Supplemental Table 2 for univariate relations between growth outcomes and demographics and prenatal cigarette/drug use.) Sixty-nine mothers were part of a pilot feasibility randomized controlled trial of prenatal choline supplementation (34 received choline; 35 placebo); the choline supplement and placebo were calorie- and iron-free (44). The 34

mother-infant pairs in the active treatment arm were excluded from analyses examining dietary choline; these infants were included in the other analyses to optimize power to detect effect modification, and choline treatment (Yes/No) was included as a covariate.

Linear regression models were used to examine associations of PAE to infant anthropometric outcomes; multivariable models were used to examine these relations after adjustment for potential confounding variables. Effect modification by each of the maternal nutritional measures was examined in regression models examining the relation of PAE to each anthropometric outcome stratified by the maternal nutritional measure and confirmed in unstratified regression models regressing the anthropometric outcome on PAE, the maternal nutritional measure, and a PAE \times maternal nutritional measure interaction term. Given the low power of interaction terms in epidemiological studies, effect modification was inferred when the *P* value for the interaction term was <0.10, as recommended by McClellan and Judd (45).

Results

The mothers in the cohort were poorly educated and socioeconomically disadvantaged (Table 1). Heavy-drinking mothers were 2.1 years older than controls, had completed 0.7 fewer years of school, and scored 0.4 SD lower on the Hollingshead socioeconomic index (46). On average, women were recruited toward the end of the second trimester, with heavy-drinking pregnant women enrolling 3 weeks earlier than abstainers/lightdrinkers. Few women developed medical problems after recruitment (9% gestational hypertension; <5% gestational diabetes or pre-eclampsia), with no differences between drinking groups. Heavy-drinking mothers averaged 4.4 oz (132 mL) AA (the equivalent of ~7.3 standard drinks) per occasion on 2.2 d/week around time of conception and 4.3 oz (129.0 mL) AA (~7.2 standard drinks) per occasion on 1.3 days across pregnancy. Binge drinking among drinking mothers was prevalent, with 92% averaging ≥ 2 oz (60 mL) AA/occasion. All controls abstained from drinking during pregnancy except for 7 women who reported light drinking (1-3 occasions for 4 women, monthly for 2, once weekly for 1; none of the 7 reported any binge drinking) and 1 woman who drank 2.1 oz (63 mL) AA (~3.5 drinks) on 1 occasion. Although smoking was prevalent, with heavy-drinking women more likely to smoke than controls, number of cigarettes per day was similar and generally low in both groups (86% < 0.5packs/day; $2\% \ge 1.0$ packs/day). Coexposures were prevalent, with 25% of heavy-drinking women reporting marijuana use (compared with 11% of control women) and 12% reporting methamphetamine use (compared with 16% of controls); no woman reported methaqualone, cocaine, or opiate use. Alcohol consumption was not related to weeks gestation at delivery, and most women (88%) had full-term pregnancies. Almost all mothers breastfed; roughly half reported supplementing with formula, with no group differences.

Maternal nutritional measures

As we have previously reported (29), maternal nutrition was similarly poor between heavy-drinking women and controls, with no group differences (Table 1). At least half of women in both groups had inadequate second/third-trimester rate of gestational

Prenatal nutrition and FASD growth restriction

TABLE 1 Maternal and infant sample characteristics¹

$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Controls $(n = 71)$		Heavy-drinking mothers $(n = 118)$		
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			Mean \pm SD		Mean \pm SD	
$\begin{split} \begin{array}{llllllllllllllllllllllllllllllllllll$		n	or <i>n</i> (%)	n	or <i>n</i> (%)	P^2
$\begin{split} & \text{Maternal age at conception, y} & 71 & 25.5 \pm 4.9 & 118 & 27.4 \pm 6.0 & 0.011 \\ & \text{Gravidity, co.} is beinds, $\%$ & 71 & 15 \pm 1.3 & 118 & 1.9 \pm 1.6 & 0.146 \\ & \text{Education (y of school completed)} & 70 & 9.9 \pm 1.7 & 118 & 9.2 \pm 1.7 & 0.006 \\ & \text{Maritul status, non-maried, $\%$ & 71 & 23.0 \pm 7.4 & 118 & 20.4 \pm 7.1 & 0.014 \\ & \text{We gestation at enrollment} & 71 & 25.1 \pm 5.1 & 118 & 23.2 \pm 5.7 & <0.001 \\ & \text{Gestational hypertension, n (\%)} & 70 & 6(.8.6) & 116 & 10(.8.6) & 0.991 \\ & \text{Gestational hypertension, n (\%)} & 70 & 1(.4.3) & 116 & 5(.4.3) & 0.381 \\ & \text{Toradofic and upplementation, n (\%)} & 70 & 11(.4) & 116 & 5(.4.3) & 0.324 \\ & \text{Pre-celampis, n (\%)} & 70 & 11(.4) & 116 & 59(.8.5) & 0.650 \\ & \text{Toradofic and upplementation, n (\%)} & 70 & 58(.82.9) & 116 & 99(.85.3) & 0.650 \\ & \text{Toradofic and upplementation, n (\%)} & 70 & 34(.43.0) & 111 & 0.4 \pm 0.3 & 0.232 \\ & \text{Having inadequate weight gain rate, 1 n \% & 34(.47.9) & 46(.30.0) & 0.523 \\ & \text{Indequate intake, n (\%)} & 70 & 98(.82.9) & 116 & 99(.85.3) & 0.350 \\ & \text{Torin intake Fron diet only, 2 mg/d} & 71 & 12.4 \pm 3.7 & 118 & 11.7 \pm 2.8 & 0.199 \\ & \text{Indequate intake, n (\%)} & 70 & 0.98(.6) & 118 & (100.0) & 0.958 \\ & \text{Toroin take Fron diet only, 2 mg/d} & 71 & 12.4 \pm 3.7 & 118 & 31.1.1 \pm 130.3 & 0.984 \\ & Having inadequate intake, ^n (\%) & 70 & 58(.82.9) & 116 & 99(.85.3) & 0.6550 \\ & \text{Torois supplementation most days, n (\%) & 71 & 0.94 & 0.0 \pm 0.1 & 2.2 \pm 1.2 & <0.001 \\ & \alpha AAdrinking d & 0.0 \pm 0.1 & 2.2 \pm 1.2 & <0.001 \\ & \alpha AAdrinking d & 0.0 \pm 0.1 & 1.2 \pm 1.4 & <0.019 \\ & 0.6 AAd1 & 0.0 \pm 0.1 & 1.2 \pm 1.4 & <0.019 \\ & 0.6 AAd2 & 0.0 \pm 0.1 & 1.2 \pm 1.4 & <0.020 \\ & 0.6 AAd1 & 0.0 \pm 0.1 & 1.2 \pm 1.4 & <0.020 \\ & 0.6 AAd1 & 0.0 \pm 0.1 & 1.2 \pm 1.4 & <0.001 \\ & 0.6 AAd1 & 0.0 \pm 0.1 & 1.2 \pm 1.2 & <0.001 \\ & 0.6 AAd1 & 0.0 \pm 0.1 & 1.2 \pm 1.2 & <0.001 \\ & 0.6 AAd1 & 0.0 \pm 0.1 & 1.2 \pm 1.2 & <0.001 \\ & 0.6 AAd2 & 0.0 \pm 0.1 & 1.2 \pm 1.4 & <0.019 \\ & 0.6 AAd2 & 0.0 \pm 0.1 & 1.2 \pm 1.4 & <0.020 \\ & 0.6 AAd2 & 0.0 \pm 0.1 & 1.2 \pm 1.4 & 0.020 \\ & 0.6 AAd3 $	Maternal characteristics					
$ \begin{array}{c} \mbox{Gravidity} no. live birds, \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	Maternal age at conception, y	71	$25.5~\pm~4.9$	118	27.6 ± 6.0	0.011
Education (y of school completed) 70 9.9 ± 1.7 118 9.2 ± 1.7 0.006 Marial status on namied, % 71 23.0 ± 7.4 118 20.4 ± 7.1 0.014 We gestation at renollment 71 23.0 ± 7.4 118 20.4 ± 7.1 0.014 Gestational dispertension, n (%) 70 6.(8.6) 116 5.(4.3) 0.99 Gestational dispertension, n (%) 70 1.(1.4) 116 5.(4.3) 0.28 Ionofolic acid sepplementation, n (%) 70 5.6 (96.6) 99 (96.0) 0.749 Second/bitter/mester weight gain rate, kgok 68 0.4 ± 0.3 111 0.4 ± 0.3 0.230 Itom intake from det only ² mg/d 71 12.4 ± 3.7 118 11.1 ± 12.8 0.199 Indequate intake, n (%) 70 70 (98.6) 118 (100.0) 0.950 Tool supplementation most days, n (%) 73 86 (96.6) 99 99 (96.2) 0.852 Iono intake from det only ² mg/d 71 12.4 ± 3.7 118 (11.1 ± 12.8 0.190 Tool supplementation most days, n (%) 7	Gravidity: no. live births, %	71	1.5 ± 1.3	118	1.9 ± 1.6	0.146
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Education (y of school completed)	70	9.9 ± 1.7	118	9.2 ± 1.7	0.006
Socieconomic status ³ 71 23.0 ± 7.4 118 20.4 ± 7.1 0.014 We gestation and induces, n (%) 70 $6(8.6)$ 116 $10(8.6)$ 0.994 Cestational disces, n (%) 70 $3(4.3)$ 116 $9(4.3)$ 0.994 Pro-celampsia, n (%) 70 $1(1.4)$ 116 $9(4.3)$ 0.899 Toorfoic acid stopplement on "most days," n (%) 55 (96.6) 99 (96.0) 0.793 Becond/third-intestre weight gain rate, $\frac{1}{n}$ % 34 (17.9) 65 (58.6) 0.2923 Having inadequate intake, $\frac{1}{n}$ (%) 71 223.67 ± 894.8 118 224.77 ± 806.1 0.332 Ion intak for for odiet only," mg/d 71 24.17 ± 37 118 11.7 \pm 2.8 0.199 Inadequate intake, " n (%) 70 $84(82.9)$ 116 $99(85.3)$ 0.650 Toor istak for for diet only," mg/d 71 11.1 ± 0.3 11.1 ± 10.3 0.99 Inon itak for for diet only," mg/d 71 31.5 ± 119.3 118 (100.0) 0.650 Toor istak for for diet only, mg	Marital status, no. married, %	71	30 (42.3)	118	34 (28.8)	0.059
Wk gestalon at enrollment 71 $2.6.\pm 5.1$ 118 $3.2.\pm 5.7$ <0.001 Gestational prepertension, $n(\%)$ 70 $3(4.3)$ 116 $10.8(s)$ 0.991 Gestational prepertension, $n(\%)$ 70 $3(4.3)$ 116 $5(4.3)$ 0.231 Inorfolic acid supplementation, $n(\%)$ 70 $58(82.9)$ 116 $99(85.3)$ 0.65 Took supplementon "nost days," $n(\%)$ 55 (96.6) 99(96.0) 0.749 Second/third-timester weight gain rate, kg/wk 68 0.4 ± 0.3 111 0.4 ± 0.3 0.223 Inadequate intake, $n(\%)$ 71 224.5.7 ± 894.8 118 224.7.7 ± 806.1 0.523 Inadequate intake, $n(\%)$ 70 58(82.9) 116 90(85.3) 0.650 Inadequate intake, $n(\%)$ 70 58(82.9) 116 90(85.3) 0.650 Toof is acid supplementation, $n(\%)$ 70 58(82.9) 116 90(85.3) 0.650 Toof is acid supplementation, $n(\%)$ 70 58(82.9) 116 90(85.3) 0.650	Socioeconomic status ³	71	23.0 ± 7.4	118	20.4 ± 7.1	0.014
Gestational dispertension, $n(\%)$ 70 6 (8.6) 116 10 (8.6) 0.991 Gestational dispertension, $n(\%)$ 70 1 (1.4) 116 5 (4.3) 0.394 Pre-celumpsia, $n(\%)$ 70 5 (82.9) 116 99 (95.0) 0.793 Bescond/lifth-inmestre vielpt gain rate, $t_{g}\%$ 68 0.44 0.3 11 0.44 0.3 0.3923 Bescond/lifth-inmestre vielpt gain rate, $t_{g}\%$ 8 0.44 0.3 11.0 0.44 0.3 0.323 Ioni intak form diet only, [*] mg/d 71 12.44 3.7 18 1.7.7 28.6 0.423 Ioni intak for modiet only, [*] mg/d 71 13.15 11.3 13.11.4 10.3 0.994 Having inadequate intak, [*] n (%) 70 58 (82.9) 116 99 (96.3) 0.958 Took supplement on *most days, *n (%) 70 58 (82.9) 116 99 (96.3) 0.958 Took supplement on *most days, *n (%) 70 58 (82.9) 116 9.0 2.2 1.0 0.001 <td>Wk gestation at enrollment</td> <td>71</td> <td>26.1 ± 5.1</td> <td>118</td> <td>23.2 ± 5.7</td> <td>< 0.001</td>	Wk gestation at enrollment	71	26.1 ± 5.1	118	23.2 ± 5.7	< 0.001
Gestiminal diabetes, n (%) 70 3 (4.3) 116 5 (4.3) 0.994 Pre-celampis, n (%) 70 1 (1.4) 116 5 (4.3) 0.281 Iron/folic acid supplementant on, n (%) 70 5 (66.6) 99 (96.0) 0.749 Second/hird-trimester weight gain rate, t_{ij} (%) 34 (50.0) 65 (58.6) 0.244 Dictury energy intake, t_{ik} (kuld 71 2326.7 ± 894.8 118 247.7 ± 806.1 0.523 Inadequatic intake, t_{in} (%) 71 12.4 ± 3.7 118 11.7 ± 2.8 0.199 Inadequatic intake, t_{in} (%) 70 58 (82.9) 105 108 (00.0) 0.196 Choine intake from diet only, t_{in} (%) 70 58 (82.9) 106 99 (85.3) 0.650 Took supplementarion, n (%) 70 58 (82.9) 116 54 (9.6) 0.852 Choid los at conception: 71 118 0.0 ± 0.1 1.2 ± 1.2 0.001 Ox AAd 0.0 ± 0.1 0.2 ± 1.2 0.001 0.2 ± 1.2 0.001 0.2 ± 1.2 0.001 <	Gestational hypertension, n (%)	70	6 (8.6)	116	10 (8.6)	0.991
Pre-calampsia, $n(\%)$ 70 1 (1.4) 116 5 (4.3) 0.231 Irono/folic acid supplement on "most days," $n(\%)$ 56 (96.6) 99 (96.0) 0.749 Becond/link-irmestar weight gain rate, $l_{y}\%$ 56 (96.6) 99 (96.0) 0.749 Becond/link-irmestar weight gain rate, $l_{y}\%$ 34 (50.0) 65 (58.6) 0.2023 Invining indequate weight gain rate, $l_{y}\%$ 34 (47.9) 46 (39.0) 0.233 Invining indequate intake, $l_{n}(\%)$ 71 12.4 ± 3.7 118 11.7 ± 2.8 0.199 Invining indequate intake, $l_{n}(\%)$ 63 (88.7) 105 (89.0) 0.988 106 (89.0) 0.988 Irono/folic acid supplementation, $n(\%)$ 70 58 (52.9) 116 99 (85.3) 0.650 Took supplement on "most days," $n(\%)$ 58 56 (96.6) 9 99 (96.2) 0.832 Alcobol and drig use Alcobol is act conception: 71 118 1.6 ± 1.6 <0.001	Gestational diabetes, n (%)	70	3 (4.3)	116	5 (4.3)	0.994
$\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	Pre-eclampsia, n (%)	70	1 (1.4)	116	5 (4.3)	0.281
Took supplement on "most days," n (%) 55 (96.6) 99 (96.0) 0.749 Becond/hind-trimester weight gain rate, $\frac{1}{n}$ % 34 (50.0) 65 (58.6) 0.254 Braing inadequate wight gain rate, $\frac{1}{n}$ % 34 (47.9) 46 (39.0) 0.252 Inadequate intake, n (%) 71 232.6,74 84.8 224.7,74 80.6,10 0.152 Inadequate intake, n (%) 71 234.4 37 18 11.7 ± 2.8 0.199 Inadequate intake, n (%) 63 (88.7) 105 (89.0) 0.988 Iron intake from diet only, ⁸ mg/d 71 31.1 ± 130.3 0.984 Ironic aid supplement on "most days," n (%) 58 56 (96.6) 9 95 (96.2) 0.852 Alcohol and drug use Alcohol and drug use 1.1 ± 130.3 4.4 ± 2.9 -0.001 Oz AAd 0.0 ± 0.1 1.8 -2.2 ± 1.2 -0.001 Or AAdd 0.0 ± 0.0 0.9 ± 1.2 -0.001 Or AAdd 0.0 ± 0.0 1.3 ± 1.0 -0.001 Or AAdd 0.0 ± 0.1 1.3 ± 0.4 -0.002	Iron/folic acid supplementation, n (%)	70	58 (82.9)	116	99 (85.3)	0.650
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Took supplement on "most days," n (%)		56 (96.6)		99 (96.0)	0.749
Having inadequate wight gain rate, $^n \%$ 34 (50.0) 65 (58.6) 0.244 Dietary energy intake, $^h XedM$ 71 232.67 ± 894.8 118 224.77 ± 806.1 0.532 Inadequate intake, $^n n (\%)$ 71 12.42 ± 3.7 118 11.7 ± 2.8 0.199 Inadequate intake, $^h n (\%)$ 70 86.0 118 (100.0) 0.196 Choline intake from diet only, $^h n (\%)$ 70 58 (82.7) 1105 (89.0) 0.038 Iroor Jolic acid supplementation, $n (\%)$ 70 58 (82.9) 116 99 (85.3) 0.650 Took supplement on "most days," $n (\%)$ 71 58 (55.0) 99 95 (96.2) 0.852 Alcohol use a conception: 71 118 1.6 ± 1.6 <0.001	Second/third-trimester weight gain rate, kg/wk	68	0.4 ± 0.3	111	0.4 ± 0.3	0.923
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Having inadequate weight gain rate, ⁴ $n \%$		34 (50.0)		65 (58.6)	0.264
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Dietary energy intake, ³ kcal/d	71	2326.7 ± 894.8	118	2247.7 ± 806.1	0.532
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Inadequate intake, $n(\%)$		34 (47.9)		46 (39.0)	0.230
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Iron intake from diet only, ³ mg/d	71	12.4 ± 3.7	118	11.7 ± 2.8	0.199
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Inadequate intake, $n(\%)$		70 (98.6)		118 (100.0)	0.196
Having inadequate intake," n (%) 63 (88.7) 105 (89.0) 0.958 Toor/Gic acid supplementation, n (%) 70 58 (52.9) 116 99 (95.3) 0.650 Took supplement on "most days," n (%) 58 56 (96.6) 99 95 (96.2) 0.852 Alcohol use at conception: 71 118 $acc AAd$ 0.0 ± 0.1 1.6 ± 1.6 <0.001	Choline intake from diet only, ⁶ mg/d	71	311.5 ± 119.3	118	311.1 ± 130.3	0.984
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Having inadequate intake, $n(\%)$		63 (88.7)		105 (89.0)	0.958
Took supplement on "most days," n (%) 58 50 (96.6) 99 95 (96.2) 0.852 Alcohol use at conception: 71 118 ox AAd 0.0 ± 0.1 1.6 ± 1.6 <.0.001	Iron/folic acid supplementation, n (%)	70	58 (82.9)	116	99 (85.3)	0.650
Alcohol and drug use 11 118 Alcohol use at conception: 71 0.0 \pm 0.1 1.6 \pm 1.6 <-0.001	Took supplement on "most days," n (%)	58	56 (96.6)	99	95 (96.2)	0.852
Alcohol use at conception: 71 118 oz AAd 0.0 ± 0.1 1.6 ± 1.6 <0.001	Alcohol and drug use	- 1		110		
02 AAd 0.0 ± 0.1 1.6 ± 1.6 -0.001 02 AAd 0.0 ± 0.1 2.2 ± 1.2 -0.001 Drinking days/wk 0.0 ± 0.1 2.2 ± 1.2 -0.001 Alcohol use across pregnancy: 71 118 -0.001 02 AAd 0.0 ± 0.0 0.9 ± 1.2 -0.001 02 AAd 0.0 ± 0.2 1.3 ± 1.0 -0.001 02 AAd 0.0 ± 0.2 1.3 ± 1.0 -0.001 02 AAd 0.0 ± 0.2 1.3 ± 1.0 -0.001 02 AAd 0.0 ± 0.2 1.3 ± 1.0 -0.001 02 AAd 0.0 ± 0.2 1.3 ± 1.0 -0.001 $02 carcter side and gards 5.8 \pm 3.8 6.7 \pm 4.2 0.222 Reporting cigartet sonking, n (%) 80 11 (15.5) 118 14 (1.1.9) 0.47 Methamphetamine use, n (%) 80 11 (15.5) 118 14 (1.1.9) 0.44 \pm 5.0 0.059 Infant characteristics Wetks gestation at delivery 71 33 (46.5) 118 8.575.5 0.017 $	Alcohol use at conception:	71	0.0 + 0.1	118		0.001
$0.2 \text{ AA/drinking d}$ 0.1 ± 0.3 4.4 ± 2.9 <0.001	oz AA/d		0.0 ± 0.1		1.6 ± 1.6	< 0.001
Draking days/wk 0.0 ± 0.1 2.2 ± 1.2 <0001 Alcohol use across pregnancy: 71 118 oz AA/d 0.0 ± 0.0 0.9 ± 1.2 <0.001	oz AA/drinking d		0.1 ± 0.3		4.4 ± 2.9	< 0.001
Alcohol use across pregnancy: 71 118 oz AA/d 0.0 ± 0.0 0.9 ± 1.2 -0.001 oz AA/d 0.1 ± 0.4 4.3 ± 2.4 -0.001 Drinking days/wk 0.0 ± 0.2 1.3 ± 1.0 -0.001 Reporting cigarette smoking, n (%) 71 49 (60.0) 118 101 (85.6) 0.006 Cigarettes/d among smokers 5.8 ± 3.8 6.7 ± 4.2 0.222 Reporting marijuana use, n (%) 80 11 (15.5) 118 14 (11.9) 0.476 Methamphetamine use, n (%) 80 11 (15.5) 118 14 (11.9) 0.476 Methamphetamine umong users 10.2 ± 8.9 4.4 ± 5.0 0.069 Infant chracteristics $Wecks gestation at delivery 71 39.1 \pm 1.8 118 38.8 \pm 2.0 0.369 Preterm delivery (<37 wk), n (%) 9 (12.7) 15 (12.7) 0.994 Infant birthweight (< 2500 g), %$	Drinking days/wk		0.0 ± 0.1	110	2.2 ± 1.2	< 0.001
oz AA/d 0.0 ± 0.0 0.9 ± 1.2 <0.001	Alcohol use across pregnancy:	71		118		0.001
oz AA/drinking d 0.1 \pm 0.4 4.3 \pm 2.4 <0.001	oz AA/d		0.0 ± 0.0		0.9 ± 1.2	< 0.001
Drinking daysWk 0.0 ± 0.2 1.5 ± 1.0 <0.000Reporting cigarette smoking, n (%)7149 (60.0)118101 (85.6)0.006Cigarettes/d among smokers 5.8 ± 3.8 6.7 ± 4.2 0.222Reporting marijuana use, n (%)718 (11.3)11829 (24.6)0.026Marijuana d/mo among users 4.0 ± 4.7 9.7 ± 9.4 0.108Reporting methamphetamine use, n (%)8011 (15.5)11814 (11.9)0.476Methamphetamine d/mo among users 10.2 ± 8.9 4.4 ± 5.0 0.069Infant characteristics 0.2 ± 8.9 4.4 ± 5.0 0.369Weeks gestation at delivery7139.1 ± 1.8 11838.8 ± 2.0 0.369Preterm delivery (< <37 wk), n (%) 9 (12.7)15 (12.7)0.994Infant sex, no. female (%)7133 (46.5)11866 (55.9)0.208Infant birthweight (< 2500 g), % 8 (11.4)31 (26.3)0.015No. iow birthweight (< 2500 g), %6160 (98.4)103100 (97.1)0.609Weeks formula feeding, %6128 (45.9)10357 (55.3)0.242Weeks formula feeding, %61 -1.3 ± 1.3 98 -1.7 ± 1.4 0.053Weight61 -0.8 ± 1.2 98 -1.3 ± 1.3 0.021Weight61 -0.8 ± 1.2 98 -1.3 ± 1.3 0.021Weight61 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight69 0.1 ± 1.9 1	oz AA/drinking d		0.1 ± 0.4		4.3 ± 2.4	< 0.001
Reporting cigarette sinoking, n (%)/149 (80.0)118101 (85.0)0.000Cigarette sinoking smokers5.8 ± 3.86.7 ± 4.20.222Reporting marijuana use, n (%)718 (11.3)11829 (24.6)0.026Marijuana d/mo among users4.0 ± 4.79.7 ± 9.40.108Reporting methamphetamine d/mo among users10.2 ± 8.94.4 ± 5.00.069Infant characteristics10.2 ± 8.94.4 ± 5.00.069Weeks gestation at delivery7133 (46.5)11838.8 ± 2.00.369Pretern delivery (<37 wk), n (%)9 (12.7)15 (12.7)0.994Infant birthweight (<2500 g), %	Drinking days/wk	71	0.0 ± 0.2	110	1.3 ± 1.0	< 0.001
Cligaretics/C	Reporting cigarette smoking, n (%)	/1	49 (00.0)	118	101 (85.6)	0.000
Reporting marijuana use, $n(\%)$ /18(1.5)11829 (24.6)0.020Marijuana d/mo among users 4.0 ± 4.7 9.7 ± 9.4 0.108Reporting methamphetamine use, $n(\%)$ 8011 (15.5)11814 (11.9)0.476Methamphetamine d/mo among users 10.2 ± 8.9 4.4 ± 5.0 0.009Infant characteristics9 (12.7)15 (12.7)0.994Mexes gestation at delivery (<37 wk), $n(\%)$ 9 (12.7)15 (12.7)0.994Infant sex, no. female (%)7133 (46.5)11866 (65.9)0.208Infant birthweight, g703078.8 ± 534.5 1182876.8 ± 570.5 0.017No. low birthweight (<2500 g), %	Cigarettes/d among smokers	71	5.8 ± 3.8	110	6.7 ± 4.2	0.222
Marijuana Union almong users 4.0 ± 4.7 9.7 ± 9.4 0.108 Reporting methamphetamine use, n (%)8011 (15.5)11814 (11.9) 0.476 Methamphetamine d/mo among users 10.2 ± 8.9 4.4 ± 5.0 0.069 Infant characteristics 0.2 ± 8.9 4.4 ± 5.0 0.069 Weeks gestation at delivery71 39.1 ± 1.8 118 38.8 ± 2.0 0.369 Preterm delivery (<37 wk), n (%) 9 (12.7) 15 (12.7) 0.994 Infant sex, no. female (%)71 33 (46.5)118 66 (55.9) 0.208 Infant birthweight, g70 3078.8 ± 534.5 118 2876.8 ± 570.5 0.017 No. low birthweight (<2500 g), %	Reporting marijuana use, n (%)	/1	8 (11.3)	118	29 (24.6)	0.026
Reporting metamine date, $h(\infty)$ 8011 (15.3)11 (1814 (11.9)0.4.70Methamphetamine d/mo among users 10.2 ± 8.9 4.4 ± 5.0 0.069Infant characteristicsWeeks gestation at delivery71 39.1 ± 1.8 118 38.8 ± 2.0 0.369Preterm delivery (<37 wk), $n(\%)$ 9 (12.7)15 (12.7)0.994Infant birthweight, g70 3078.8 ± 534.5 1182876.8 \pm 570.50.017No. low birthweight (<2500 g), %	Marijuana d/mo among users	20	4.0 ± 4.7	110	9.7 ± 9.4	0.108
Internal pretaining during due is 10.2 ± 8.9 4.4 ± 3.0 0.009 Infant characteristicsWeeks gestation at delivery71 39.1 ± 1.8 118 38.8 ± 2.0 0.369 Pretern delivery (<37 wk), n (%)	Reporting methamphetamine use, $n(\%)$	80	11(15.5) 10.2 ± 8.0	118	14(11.9)	0.470
Inflat characteristics 71 39.1 ± 1.8 118 38.8 ± 2.0 0.369 Pretern delivery (<37 wk), n (%) 9 (12.7) 15 (12.7) 0.994 Infant sex, no. female (%) 71 33 (46.5) 118 66 (55.9) 0.208 Infant birthweight, g 70 3078.8 ± 534.5 118 2876.8 ± 570.5 0.017 No. low birthweight (<2500 g), %	Infant characteristics		10.2 ± 6.9		4.4 ± 5.0	0.009
Weeks gestation at definery1139.1 \pm 1.811836.8 \pm 2.00.309Preterm delivery (<37 wk), n (%)	Weaks gestation at delivery	71	20.1 ± 1.9	119	28.8 ± 2.0	0.260
Infant sex, no. female (%)7133 (46.5)11866 (55.9)0.208Infant birthweight, g703078.8 \pm 534.51182876.8 \pm 570.50.017No. low birthweight (<2500 g), %	Protorm dolivery (< 27 wk) n (%)	/1	9.1 ± 1.0 0 (12.7)	110	36.6 ± 2.0	0.309
Infant Sex, io. female (%)7133 (40.3)11300 (35.3)0.206Infant birthweight (703078.8 \pm 534.51182876.8 \pm 570.50.017No. low birthweight (<2500 g), %	Infant say, no, famila $(%)$	71	9 (12.7)	119	15(12.7)	0.994
Init of function 10° 3078.3 ± 394.3 118° 2870.3 ± 370.3 0.017° No. low birthweight (<2500 g), %	Infant Sex, no. lemaie (%)	71	3078.8 ± 534.5	118	2876.8 ± 570.5	0.208
No. is wolf in weight (<2.500 g), $\%$ is (11.4)is (12.5)is (12.5)is (12.5)No. small for gestational age, 10^{10} 7013 (18.6)11843 (36.4)0.010No. reporting breastfeeding, $\%$ 6160 (98.4)103100 (97.1)0.609Weeks breastfed6027.4 \pm 6.910027.4 \pm 5.50.991No. reporting formula feeding, $\%$ 6128 (45.9)10357 (55.3)0.242Weeks formula given2818.6 \pm 8.25718.9 \pm 7.20.8782-wk z-scores ¹¹ 10.1 \pm 1.398-1.7 \pm 1.40.053Weight61-0.8 \pm 1.298-1.3 \pm 1.30.021Weight-for-length610.1 \pm 1.0980.1 \pm 1.10.702Head circumference61-0.4 \pm 1.298-0.8 \pm 1.40.00112-mo z-scores ¹¹ 1-0.72<0.001	No. low birthweight (< 2500 c) %	70	$30/8.6 \pm 334.3$ 8 (11.4)	110	$28/0.8 \pm 3/0.3$	0.017
No. reporting breastfeeding, % 61 60 110 110 100 97.1 0.010 No. reporting breastfeeding, % 61 60 98.4 103 100 97.1 0.609 Weeks breastfed 60 27.4 \pm 6.9 100 27.4 \pm 5.5 0.991 No. reporting formula feeding, % 61 28 48.5 57 18.9 \pm 7.2 0.878 Weeks formula given 28 18.6 \pm 8.2 57 18.9 \pm 7.2 0.878 2-wk z-scores ¹¹ 61 -1.3 ± 1.3 98 -1.7 ± 1.4 0.053 Weight 61 -0.8 ± 1.2 98 -1.3 ± 1.3 0.021 Weight-for-length 61 -0.4 ± 1.2 98 -0.8 ± 1.4 0.040 12-mo z-scores ¹¹ 12-mo z-scores ¹¹ 11 -0.72 ± 1.2 <0.001 Weight 69 0.1 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight-for-length 68 -0.8 ± 0.9 111 -0.7 ± 1.2 <0.001 Weight-for-length 68 0.6 ± 0.9 111 0.1 ± 1.1 $<$	No. small for gestational age $\frac{10}{6}$	70	13 (18.6)	118	43(364)	0.013
Weeks breastfed 61 $00(0.4.7)$ $100(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ $0000(0.1.7)$ 00001 Weight 61 -1.3 ± 1.3 98 -1.7 ± 1.4 0.053 0001 Weight-for-length 61 -0.8 ± 1.2 98 -1.3 ± 1.3 0.021 Weight-for-length 61 -0.4 ± 1.2 98 -0.8 ± 1.4 0.040 12-mo z-scores ¹¹ Length 68 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight-for-length	No reporting breastfeeding %	61	60 (98 4)	103	100(97.1)	0.010
Weeks formula feeding, % 60 21.4 ± 0.9 100 21.4 ± 0.9 0.971 No. reporting formula feeding, % 61 28 (45.9) 103 57 (55.3) 0.242 Weeks formula given 28 18.6 ± 8.2 57 18.9 ± 7.2 0.878 2-wk z-scores ¹¹ 61 -1.3 ± 1.3 98 -1.7 ± 1.4 0.053 Weight 61 -0.8 ± 1.2 98 -1.3 ± 1.3 0.021 Weight-for-length 61 0.1 ± 1.0 98 0.1 ± 1.1 0.702 Head circumference 61 -0.4 ± 1.2 98 -0.8 ± 1.4 0.040 12-mo z-scores ¹¹ Length 68 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight 69 0.1 ± 0.9 111 -0.7 ± 1.2 <0.001 Weight-for-length 68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001 Weight-for-length 68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001 MuAC 69 1.1 ± 0.9 111 0.6 ± 1.1 <td>Weeks breastfed</td> <td>60</td> <td>27.4 ± 6.9</td> <td>100</td> <td>27.4 ± 5.5</td> <td>0.009</td>	Weeks breastfed	60	27.4 ± 6.9	100	27.4 ± 5.5	0.009
Weeks formula given 28 18.6 ± 8.2 57 18.9 ± 7.2 0.242 Weeks formula given 28 18.6 ± 8.2 57 18.9 ± 7.2 0.878 2-wk z-scores ¹¹ 61 -1.3 ± 1.3 98 -1.7 ± 1.4 0.053 Weight 61 -0.8 ± 1.2 98 -1.3 ± 1.3 0.021 Weight-for-length 61 0.1 ± 1.0 98 0.1 ± 1.1 0.702 Head circumference 61 -0.4 ± 1.2 98 -0.8 ± 1.4 0.040 12-mo z-scores ¹¹ Length 68 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight-for-length 68 0.6 ± 0.9 111 -0.7 ± 1.2 <0.001 Weight-for-length 68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001 Weight-for-length 68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001 MUAC 69 1.1 ± 0.9 111 0.6 ± 1.1 <0.001	No reporting formula feeding %	61	27.4 ± 0.7 28 (45 9)	100	57(553)	0.242
2-wk z-scores ¹¹ 23 10.5 \pm 0.2 57 10.5 \pm 1.2 0.576 2-wk z-scores ¹¹ 61 -1.3 \pm 1.3 98 -1.7 \pm 1.4 0.053 Weight 61 -0.8 \pm 1.2 98 -1.3 \pm 1.3 0.021 Weight-for-length 61 0.1 \pm 1.0 98 0.1 \pm 1.1 0.702 Head circumference 61 -0.4 \pm 1.2 98 -0.8 \pm 1.4 0.040 12-mo z-scores ¹¹ Length 68 -0.8 \pm 0.9 111 -1.5 \pm 1.1 <0.001	Weeks formula given	28	186 ± 82	57	180 ± 72	0.242
Length 61 -1.3 ± 1.3 98 -1.7 ± 1.4 0.053 Weight 61 -0.8 ± 1.2 98 -1.3 ± 1.3 0.021 Weight-for-length 61 0.1 ± 1.0 98 0.1 ± 1.1 0.702 Head circumference 61 -0.4 ± 1.2 98 -0.8 ± 1.4 0.040 12-mo z-scores ¹¹ Length 68 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight 69 0.1 ± 0.9 111 -0.7 ± 1.2 <0.001 Weight-for-length 68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001 Weight-for-length 69 0.1 ± 0.9 111 0.1 ± 1.1 <0.001 MUAC 69 1.1 ± 0.9 111 0.6 ± 1.1 <0.001	2-wk z-scores ¹¹	20	10.0 ± 0.2	57	10.9 ± 7.2	0.070
Weight 61 -0.8 ± 1.2 98 -1.3 ± 1.3 0.021 Weight-for-length 61 -0.8 ± 1.2 98 -1.3 ± 1.3 0.021 Weight-for-length 61 0.1 ± 1.0 98 0.1 ± 1.1 0.702 Head circumference 61 -0.4 ± 1.2 98 -0.8 ± 1.4 0.040 12-mo z-scores ¹¹ Length 68 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight 69 0.1 ± 0.9 111 -0.7 ± 1.2 <0.001 Weight-for-length 68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001 MUAC 69 1.1 ± 0.9 111 0.6 ± 1.1 <0.001	Length	61	-13 + 13	98	-17 + 14	0.053
Weight-for-length 61 0.0 ± 1.2 70 1.5 ± 1.5 0.021 Weight-for-length 61 0.1 ± 1.0 98 0.1 ± 1.1 0.702 Head circumference 61 -0.4 ± 1.2 98 -0.8 ± 1.4 0.040 12-mo z-scores ¹¹ Length 68 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight 69 0.1 ± 0.9 111 -0.7 ± 1.2 <0.001 Weight-for-length 68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001 MUAC 69 1.1 ± 0.9 111 0.6 ± 1.1 <0.001	Weight	61	-1.5 ± 1.5 -0.8 ± 1.2	98	-1.7 ± 1.4 -1.3 ± 1.3	0.033
Head circumference 61 0.1 ± 1.0 70 0.1 ± 1.1 0.702 Head circumference 61 -0.4 ± 1.2 98 -0.8 ± 1.4 0.040 12-mo z-scores ¹¹ Length 68 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight 69 0.1 ± 0.9 111 -0.7 ± 1.2 <0.001 Weight-for-length 68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001 MUAC 69 1.1 ± 0.9 111 0.6 ± 1.1 <0.001	Weight-for-length	61	0.0 ± 1.2 0.1 ± 1.0	98	0.1 + 1.1	0.702
12-mo z-scores ¹¹ 68 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Length68 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight69 0.1 ± 0.9 111 -0.7 ± 1.2 <0.001 Weight-for-length68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001 MUAC69 1.1 ± 0.9 111 0.6 ± 1.1 <0.001	Head circumference	61	-0.4 ± 1.0	98	-0.8 ± 1.4	0.040
Length 68 -0.8 ± 0.9 111 -1.5 ± 1.1 <0.001 Weight 69 0.1 ± 0.9 111 -0.7 ± 1.2 <0.001 Weight-for-length 68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001 MUAC 69 1.1 ± 0.9 111 0.6 ± 1.1 <0.001	12-mo z-scores ¹¹	01	V.I ± 1.2	20	0.0 ± 1.7	0.040
Weight69 0.1 ± 0.9 111 -0.7 ± 1.2 <0.001Weight-for-length68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001	Length	68	-0.8 ± 0.9	111	-1.5 ± 1.1	< 0.001
Weight-for-length68 0.6 ± 0.9 111 0.1 ± 1.1 <0.001MUAC69 1.1 ± 0.9 111 0.6 ± 1.1 <0.001	Weight	69	0.1 ± 0.9	111	-0.7 + 1.2	< 0.001
MUAC 69 1.1 ± 0.9 111 0.6 ± 1.1 <0.001	Weight-for-length	68	0.6 ± 0.9	111	0.1 ± 1.2 0.1 ± 1.1	< 0.001
	MUAC	69	1.1 ± 0.9	111	0.6 ± 1.1	< 0.001

(Continued)

	Co	pontrols ($n = 71$)	Heavy-dri	Heavy-drinking mothers $(n = 118)$	
	n	Mean \pm SD or <i>n</i> (%)	n	Mean \pm SD or <i>n</i> (%)	P^2
Triceps skinfold thickness Head circumference 12-mo biceps skinfold thickness, mm	69 69 69	$\begin{array}{c} 0.6 \pm 1.1 \\ - 0.2 \pm 0.9 \\ 6.5 \pm 2.1 \end{array}$	111 111 111	$\begin{array}{c} 0.0 \pm 1.3 \\ - 0.8 \pm 1.1 \\ 5.5 \pm 1.8 \end{array}$	0.002 <0.001 0.001

 1 AA, absolute alcohol (1 oz AA = 30 mL AA = 1.67 standard drinks); MUAC, midupper arm circumference.

²From independent samples *t* tests for continuous outcomes, χ^2 for binary outcomes, and linear-by-linear association for ordinal outcomes. ³Score from the Hollingshead scale (46).

 4 Defined as <0.42 kg/wk (38).

⁵From 3 multipass 24-h recall dietary interviews.

⁶Defined as energy intake below the estimated energy requirement based on height, weight, activity level, and weeks gestation (41, 42).

⁷Defined as dietary iron intake <23 mg/d for women aged <19 y; <22 mg/d for ages ≥19 y (59).

⁸From 3 choline-indicated FFQ interviews (39).

 9 Defined as dietary choline intake <450 mg/d (60).

¹⁰Defined as birthweight <10th percentile for gestational age (61).

¹¹Age- and sex-specific *z*-scores from WHO norms (43).

weight gain, and 42% of the cohort reported inadequate dietary energy intake, with no group differences. Over 80% of the women reported being prescribed prenatal iron/folic acid supplements, with the vast majority reporting taking the supplements on "most days." All but 1 woman reported inadequate iron intake (from diet only). Almost 90% reported inadequate choline intake (from diet only), with no group differences.

Relation of prenatal alcohol consumption and nutritional measures to infant anthropometric outcomes

Infants born to heavy-drinking mothers were smaller than infants born to controls across almost every measure at 2 weeks and at 12 months (Table 1). In univariate models (Table 2), average prenatal AA per day was related to smaller infant length, weight, and head circumference z-scores at age 2 weeks, and smaller length, weight, MUAC, TSF, and head circumference zscores at 12 months. After adjustment for potential confounders, average daily PAE (AA per day) was related to smaller infant length and head circumference at ages 2 weeks and 12 months, and smaller weight, MUAC, and TSF at 12 months. The magnitudes of the associations between PAE and length and weight were larger at age 12 months than at 2 weeks; this pattern was not seen for head circumference. When adjusting for 2-week z-scores, the magnitudes of the associations of PAE to 12-month length and head circumference were reduced by 16% and 49%, respectively, whereas the magnitudes of the associations of PAE to 12-month weight, weight-for-length, and MUAC (adjusted for 2-week weight-for-length z-score) increased (by 16%, 50%, and 44%, respectively).

Univariate association trends (P < 0.10) were seen between rate of maternal second/third-trimester gestational weight gain and larger 12-month length, weight, MUAC, and head circumference (Table 2). Association trends (P < 0.10) were also seen between maternal dietary iron and larger head circumference at 2 weeks (multivariable model, adjusting for potential confounders) and 12 months (in univariate but not multivariable models). Maternal dietary energy adequacy and choline intake were not related to any anthropometric outcome.

Effect modification by maternal nutritional measures in fetal alcohol growth restriction

Figure 1 compares the relations of average daily PAE (AA per day) to each growth outcome stratified by maternal nutritional measures (values shown in **Supplemental Table 3**). Associations between alcohol exposure and 12-month length, weight, MUAC, and head circumference and a trend association with TSF were only apparent in infants born to mothers with inadequate second/third-trimester gestational weight gain rate. Effect modification by weight gain rate was confirmed in regression models with an inadequate weight gain (Yes/No) × alcohol interaction term for 12-month length (interaction term P = 0.025), weight (interaction term P = 0.037), MUAC (interaction term P = 0.030).

Associations between PAE and smaller length and head circumference at 2 weeks and length, weight, MUAC, TSF, and head circumference at 12 months were only apparent in infants born to mothers in the lowest or middle tertiles for dietary energy adequacy. The magnitude of the association of PAE to 2-week weight was larger in infants born to mothers in the middle tertile for dietary energy adequacy than the highest tertile. Effect modification by dietary energy adequacy was confirmed in regression models with a dietary energy adequacy × alcohol interaction term for 2-week length (interaction term P = 0.031) and weight (interaction term P = 0.016).

The relations of PAE to 2-week length and 12-month length, weight, weight-for-length, MUAC, TSF, and head circumference were only seen in infants born to mothers in the lowest or middle tertiles for dietary iron intake. Effect modification by dietary iron intake was confirmed in regression models with an iron × alcohol interaction term for 2-week length (interaction term P = 0.077) and 12-month weight (interaction term P = 0.054), weight-forlength (interaction term P = 0.076), and head circumference (interaction term P = 0.089).

The associations of PAE to 2-week length and weight were only seen in infants born to women in the lowest tertile for dietary choline, and the effect size of PAE-related 12-month head TABLE 2 Relation of prenatal alcohol exposure and maternal nutritional measures to fetal and postnatal growth outcomes¹

	~	A/d (logged values									
			Multivariable adiusting for	Gestational weigh	t gain rate, kg/wk	Dietary energ	y adequacy ²	Dietary irc	on, ³ mg/d	Dietary cho	line, ⁴ g/d
	Univariate	Multivariable	2-wk z-score ⁵	Univariate	Multivariable	Univariate	Multivariable	Univariate	Multivariable	Univariate	Multivariable
2-wk z-scores ⁶ ($n = 98$ exposed, 6	l controls)										
Length	-0.71^{**}	-0.51*		0.38	0.31	0.12	0.14	0.05	0.04	0.26	0.43
	(-1.24, -0.18)	(-0.99, -0.03)		(-0.36, 1.13)	(-0.32, 0.94)	(-0.33, 0.56)	(-0.24, 0.53)	(-0.02, 0.12)	(-0.02, 0.10)	(-1.50, 2.02)	(-1.08, 1.95)
Weight	-0.51^{*} (-1.01,	-0.32		0.23	0.15	0.10	0.11	0.05	0.04	-0.20	-0.07
	-0.02)	(-0.76, 0.12)		(-0.45, 0.92)	(-0.42, 0.71)	(-0.31, 0.51)	(-0.24, 0.46)	(-0.02, 0.11)	(-0.02, 0.09)	(-1.89, 1.49)	(-1.47, 1.33)
Weight-for-length	0.17	0.26	I	-0.15	-0.23	0.03	-0.03	0.01	0.01	-0.43	-0.41
	(-0.25, 0.59)	(-0.20, 0.71)		(-0.76, 0.46)	(-0.86, 0.39)	(-0.32, 0.38)	(-0.39, 0.33)	(-0.05, 0.06)	(-0.05, 0.06)	(-1.85, 1.00)	(-1.83, 1.01)
Head circumference	-0.62^{*}	-0.54^{*}	I	0.31	0.26	0.03	0.04	0.05	0.05^{\dagger}	-0.61	-0.43
	(-1.14, -0.11)	(-1.00, -0.09)		(-0.39, 1.01)	(-0.32, 0.84)	(-0.40, 0.45)	(-0.33, 0.41)	(-0.02, 0.12)	(-0.01, 0.10)	(-2.37, 1.16)	(-1.90, 1.05)
12-mo z-scores ⁶ ($n = 111$ exposed,	, 69 controls)										
Length	-0.83^{***}	-0.67^{***}	-0.56^{**}	0.51°	0.33	0.09	-0.07	0.04	0.02	-0.32	-0.40
	(-1.21, -0.45)	(-1.02, -0.31)	(-0.92, -0.20)	(-0.04, 1.06)	(-0.17, 0.82)	(-0.22, 0.40)	(-0.36, 0.22)	(-0.01, 0.09)	(-0.03, 0.06)	(-1.67, 1.02)	(-1.54, 0.74)
Weight	-0.72^{***}	-0.61^{**}	-0.71^{**}	0.50°	0.32	-0.03	-0.19	0.03	0.01	-0.66	-0.72
	(-1.12, -0.31)	(-1.02, -0.20)	(-1.15, -0.28)	(-0.07, 1.06)	(-0.23, 0.86)	(-0.35, 0.30)	(-0.51, 0.14)	(-0.03, 0.08)	(-0.04, 0.06)	(-2.03, 0.70)	(-2.00, 0.56)
Weight-for-length	-0.35^{+}	-0.32	-0.48^{*}	0.31	0.21	-0.10	-0.21	0.01	0.00	-0.62	-0.63
	(-0.75, 0.05)	(-0.74, 0.10)	(-0.96, 0.00)	(-0.23, 0.85)	(-0.34, 0.76)	(-0.41, 0.21)	(-0.53, 0.12)	(-0.04, 0.06)	(-0.05, 0.06)	(-1.91, 0.68)	(-1.93, 0.67)
MUAC	-0.48**	-0.43^{*}	-0.62^{**} (-1.05 ,	0.47^{\dagger}	0.34	0.02	-0.10	0.02	0.01	-0.67(-1.89,	-0.71
	(-0.86, -0.11)	(-0.81, -0.05)	-0.20)	(-0.05, 0.99)	(-0.17, 0.86)	(-0.28, 0.32)	(-0.41, 0.20)	(-0.03, 0.07)	(-0.04, 0.06)	0.55)	(-1.89, 0.47)
Triceps skinfold thickness	-0.56^{*}	-0.61^{*}	-0.67^{**} (-1.18 ,	0.04	0.02	-0.21	-0.24	-0.03	0.04	-1.01	-0.99
	(-1.00, -0.12)	(-1.08, -0.14)	-0.16)	(-0.58, 0.67)	(-0.63, 0.67)	(-0.56, 0.14)	(-0.61, 0.14)	(-0.08, 0.03)	(-0.01, 0.09)	(-2.50, 0.49)	(-2.50, 0.52)
Head circumference	-0.62^{***}	-0.57^{**}	-0.29^{\dagger} (-0.65 ,	0.51^{+}	0.37	0.03	-0.11	0.05^{\dagger}	0.04	-0.08	-0.12
	(-1.00, -0.25)	(-0.95, -0.18)	0.06)	(-0.02, 1.04)	(-0.15, 0.90)	(-0.28, 0.33)	(-0.42, 0.20)	(0.00, 0.10)	(-0.01, 0.09)	(-1.35, 1.19)	(-1.34, 1.10)
12-mo biceps skinfold thickness,	-0.70°	-0.75^{*}	-0.80°	0.27	0.26	-0.20	-0.21	-0.06	-0.07	-1.06	-1.01
mm	(-1.42, 0.01)	(-1.50, 0.01)	(-1.67, 0.06)	(-0.78, 1.31)	(-0.75, 1.26)	(-0.77, 0.36)	(-0.81, 0.40)	(-0.16, 0.03)	(-0.17, 0.03)	(-3.50, 1.37)	(-3.45, 1.44)
¹ Values are regression coeffic	ients (95% CI) from	linear models regr	essing infant anthr	opometric z-score	s on a given predict	or; multivariable r	nodels also include	prenatal cigarette	use (cigarettes per	day), maternal age	household

Prenatal nutrition and FASD growth restriction

socioeconomic status (46), weeks gestation at delivery, and, for all predictors except for dietary choline, whether the mother received a choline supplement as part of a pilot feasibility study; infants whose mothers received choline treatment

²Ratio of average daily energy intake (from 3 multipass 24-h recall dietary interviews) to estimated energy requirement (calculated based on mother's age, height, weight, activity level, and weeks gestation) (41, 42). (n = 34) were excluded from models including maternal choline intake. $^{\dagger}P \ge 0.10; ^{**}P \ge 0.01; ^{***}P \ge 0.01; ^{***}P \ge 0.001$. As, absolute alcohol [oz (30 nL)]; MUAC, midupper arm circumference.

³From 3 multipass 24-h recall dietary interviews.

⁴From 3 choline-indicated FFQ interviews (39).

⁵Missing for 18 exposed and 10 control infants who were measured at 12 mo but not 2 wk. MUAC and triceps skinfold z-scores and biceps skinfold models are adjusted for 2-wk weight-for-length z-score. ⁶Age- and sex-specific z-scores from WHO norms (43).



FIGURE 1 Relation of prenatal alcohol exposure to fetal and postnatal growth, stratified by 4 maternal nutritional indicators: (A) gestational weight gain; (B) prenatal dietary energy adequacy; (C) prenatal dietary iron intake; and (D) prenatal dietary choline intake. Y-axis values are raw regression coefficients with 95% CI error bars (in *z*-scores) for the effect of prenatal alcohol exposure (logged AA/d) on fetal and postnatal anthropometric *z*-scores (43) from multivariable models adjusted for potential confounders. *,†Significant effect modification (*P < 0.05; †P < 0.10) for interaction terms indicating effect modification by maternal nutritional measure, an AA/d × maternal nutritional measure interaction term, and potential confounders. Given the low power of interaction terms in epidemiological studies, effect modification was inferred when the *P* value for the interaction term was <0.10, as recommended by McClellan and Judd (45). Inadequate gestational weight gain was defined as <0.42 kg/wk (38). Tertile cutpoints: dietary energy adequacy [percentage of estimated energy requirement (41, 42)]: 94.2, 123.4; dietary iron intake (mg/d): 10.5, 13.0; dietary choline intake (mg/d): 243.5, 342.0. AA, absolute alcohol (oz); MUAC, midupper arm circumference; TSF, triceps skinfold thickness.

circumference reduction was much larger in women in the lowest tertile than the middle and highest tertiles. Effect modification by dietary choline intake was confirmed in a regression model with a choline × alcohol interaction term for all 3 outcomes (2-week length interaction term P = 0.069; 2-week weight interaction term P = 0.054; 12-month head circumference interaction term P = 0.027).

Table 3 examines the degree to which lower gestational weight gain and energy, iron, and choline intakes were seen in the same mothers. The Cohen κ statistic showed only slight agreement between gestational weight gain and the dietary measure tertiles, and only fair-to-moderate agreement between the 3 dietary measures.

Discussion

In this prenatally recruited, prospective, longitudinal birth cohort, PAE-related fetal and postnatal growth restriction were more severe in women with poorer nutrition across 4 measures: second/third-trimester gestational weight gain and dietary energy, iron, and choline intakes; in many cases growth effects were evident only in the more poorly nourished mothers. These findings provide evidence that variation in these elements of maternal nutrition across ranges commonly found in the general population can modify fetal vulnerability to PAE. Of note, there was relatively little overlap among these measures in terms of which mothers had poorer nutrition, indicating that these measures assessed specific elements of nutrition rather than serving as proxies for one another. To our knowledge, this is the first observational human study to examine the impact of maternal prenatal nutrition on fetal alcohol-related growth restriction.

Our finding that the magnitudes of the associations between PAE and weight, MUAC, and triceps skinfolds were larger after adjusting for 2-week measures is consistent with our original Cape Town and Detroit birth cohort studies, in which we demonstrated that PAE-related reductions in weight worsen in the first year of life (3, 4). These findings support the hypothesis that different mechanisms underlie pre- and postnatal growth restriction in FASD (9). PAE-related reductions in length were relatively stable from 2 weeks to 12 months, which is consistent with our previous finding that PAE-related height/length reductions are more stable through adolescence than weight reductions (11). Our finding of smaller weight-forlength z-scores in children born to heavy drinkers compared with controls and the associations of PAE to smaller MUAC and triceps skinfolds seen in this study are consistent with our previous finding of PAE-related reductions in percentage body fat, as measured with bioelectric impedance, in our original Cape Town cohort (3).

Effect modification by maternal gestational weight gain could indicate a moderating effect of overall global nutrition. Alternatively, higher gestational weight gain might protect against the teratogenic effects of alcohol consumption by decreasing fetal alcohol exposure, because higher nonfat body mass results in a larger pharmacological volume of distribution and a lower blood alcohol concentration (BAC) for a given quantity of alcohol consumed (47). Although nonnutritional factors can affect gestational weight gain, including illness and

	Same tertile <i>n</i> (%)	Different tertile n (%)	Weighted κ^1
Gestational weight gain rate vs. dietary energy adequacy ²	71 (39.7)	108 (60.3)	0.10
Gestational weight gain rate vs. dietary iron intake ³	80 (44.7)	99 (55.3)	0.17
Gestational weight gain rate vs. dietary choline intake ⁴	65 (43.6)	84 (56.6)	0.16
Dietary energy adequacy vs. dietary iron intake	117 (61.9)	72 (38.1)	0.43
Dietary energy adequacy vs. dietary choline intake	90 (57.0)	68 (43.0)	0.35
Dietary iron intake vs. dietary choline intake	101 (63.9)	57 (36.1)	0.46

TABLE 3 Comparisons of tertile agreement between maternal nutritional measures (n = 189)

 $10.00 \le \kappa \le 0.20$ denotes slight agreement; $0.21 \le \kappa \le 0.40$ denotes fair agreement; $0.41 \le \kappa \le 0.60$ denotes moderate agreement (62).

²Ratio of average daily energy intake (from 3 multipass 24-h recall dietary interviews) to estimated energy requirement (calculated based on mother's age, height, weight, activity level, and weeks gestation) (41, 42).

³From 3 multipass 24-h recall dietary interviews.

⁴From 3 choline-indicated FFQ interviews (39).

pregnancy complications, such issues were rare in our review of antenatal medical records in this cohort, suggesting that the effect modification seen was likely due to nutritional and related physiological factors. BAC is also affected by dietary energy intake. Food digestion induces ethanol metabolism in the liver, thereby decreasing BAC (48). Higher energy intake could thus lead to higher ethanol metabolism and lower levels of fetal exposure for a given quantity of alcohol. Alternatively, dietary energy intake might serve as a summative proxy for groups of micronutrients that have the potential to alter fetal vulnerability but have smaller individual effect sizes.

Maternal iron and choline intake each appeared to modify fetal vulnerability to PAE-related growth restriction. These findings are consistent with animal models and human trials demonstrating protective effects of iron (3, 14-17) and choline (19-23, 27, 49) supplementation and detrimental effects from restriction of these micronutrients. Although the mechanisms underlying effect modification by iron remain unknown, animal and human studies have demonstrated PAE-related alterations in maternal, fetal, and postnatal iron homeostasis, including ironrestricted placental iron transport, which, in animal models, can be exacerbated by poor maternal iron intake and ameliorated by maternal iron supplementation (3, 14–18). Indeed, iron restriction in utero or during infancy leads to growth restriction and deficits in neurobehavioral outcomes that are also seen in FASD, including poorer recognition memory, slower processing speed, and eyeblink conditioning deficits (33, 50-52). The mechanisms underlying the protective effects of choline supplementation are also unknown, but recent studies suggest that choline can ameliorate PAE-induced alterations in epigenetic programming in its role as a methyl donor (53, 54).

Of note, effect modification by all 4 elements of nutrition was stronger for PAE-related reductions in head circumference than for length or weight. Because head circumference is determined by both somatic and brain growth, future studies are needed to examine the degree to which these maternal nutritional elements also modify FASD neurobehavioral deficits. Animal models examining the impact of iron and choline and 2 human trials of maternal choline supplementation have demonstrated protective effects against teratogenic effects of PAE on neurodevelopment (19–23, 26, 27, 49). We have previously demonstrated that fetal alcohol growth restriction serves as a biomarker of the severity of FASD neurocognitive deficits, with the most severe deficits seen in children with both fetal and postnatal growth restriction (11).

This study had limitations common to other observational studies of prenatal exposures. The small sample size, measurement error surrounding estimates of exposures and covariates, model misspecification, and residual confounding might have led to unmeasured bias and Type 1 (false-positive) and Type 2 (falsenegative) errors. Although the 24-h dietary recall interviews included any reported alcoholic beverages, we were unable to ascertain dietary intake on Fridays or Saturdays, when women were more likely to drink. We have previously reported that because alcoholic beverages are high in energy content, the lack of differences between heavy-drinking and control women in weight, BMI, and rate of gestational weight gain indicate that heavy-drinking women maintained generally stable daily energy intake on drinking days compared with nondrinking days (i.e., they replaced food calories with alcohol calories when drinking) (29); sensitivity analyses modeling the scenario in which women replaced food with alcohol demonstrated that such replacement did not cause clinically significant differences in average daily micronutrient intake. Because detailed measures of postnatal infant diet throughout the first year of life were not available, we could not fully account for potential confounding by the child's postnatal nutrition. We have previously reported that formula, breast-, and complementary feeding practices through age 6.5 months were very similar between heavy-drinking mothers and controls (55). Given the unusually high prevalence of inadequate gestational weight gain and energy intake in this population, our findings need to be examined in populations with better nutrition. Of note, the prevalence of inadequate dietary iron and choline intake in this cohort was similar to estimates in studies of pregnant women in the United States and Canada (56-58). Because prepregnancy BMI was unavailable, a single cutoff for inadequate gestational weight gain was used. Overweight and obesity are uncommon in this impoverished community; low prepregnancy BMI is more common. Because the cutoff for adequate gestational weight gain for women with low prepregnancy BMI is higher (0.51 kg/week) than the single cutoff used here (0.42 kg/week) (38), we might have underestimated the true prevalence of inadequate gestational weight gain.

In conclusion, to our knowledge this is the first human study to examine the potential for gestational weight gain and dietary intakes of energy, iron, and/or choline in ranges found in the general population to alter fetal vulnerability to PAE-related growth restriction. Effect modification by these elements of nutrition could explain some of the variability in FASD outcomes in children with similar levels of exposure. Combined with evidence from FASD animal models, these findings support the need for additional studies examining potential maternal nutritional interventions across these domains in heavy-drinking pregnant women. Studies examining the mechanisms underlying effect modification by these maternal nutritional elements could elucidate pathophysiological mechanisms in alcohol teratogenesis. Our findings underscore the need for standardized alcohol and nutritional screening as an important part of standard prenatal care and the continuing need for development and implementation studies of psychosocial and biomedical harm reduction interventions for heavy-drinking pregnant women. Furthermore, given that the prenatal nutritional outcomes studied here are measurable in the clinical environment, they could be useful in identifying women with potential increased fetal risk of FASD, for whom intensified alcohol screening and psychosocial/behavioral and/or nutritional interventions could be warranted.

We thank our University of Cape Town and Wayne State University research staffs, including Maggie September, Beverley Arendse, Patricia O'Leary, and Patricia Solomon for their work on subject recruitment and maintenance; Sharmilah Booley and Baheya Najaar for their work in developing the choline-indicated FFQ; Catherine Lewis, Nadine Lindinger, and Stacey Hall, who performed the measurements of the infants; dietary interviewers Catherine Day, Monika Uys, and Nicola Cooper; Lori Bechard for her computation of dietary data; and Renee Sun, for her assistance with data processing. We also thank Susan Fawcus, MD, Head of Department of Obstetrics, Mowbray Maternity Hospital; the nursing and records department staff at the Hanover Park and Retreat Midwife Obstetric Units, Mowbray Maternity Hospital, Somerset Hospital, and Groote Schuur Hospital, where the mothers were recruited and the infants were born. Lastly, we extend our deep appreciation to our Cape Town study participants for their contributions to this study. The authors' responsibilities were as follows-RCC, SWJ, JLJ, MS, CPD, CDM: conceptualized the study design. SWJ, JLJ, RCC, CDM: oversaw recruitment and assessment of the longitudinal birth cohort, data acquisition and analysis, and interpretation of findings; CDM, EMM: coordinated and supervised data collection; NCD: coordinated data management and assisted with statistical analyses; RCC: conducted the data analyses and wrote the manuscript; SWJ, JLJ, MS, CPD: edited and revised the manuscript; and all authors: read and approved the final manuscript. The authors report no conflicts of interest.

Data Availability

Deidentified, individual participant data that underlie the results reported in this article (text, tables, figures, and appendices) and the study protocol, statistical analysis plan, and analytic code will be available for sharing to journal editors for any reason either before or after publication for checking and to researchers who provide a methodologically sound proposal, as determined by the authors of this article. Proposals from researchers should be directed to SWJ (sandra.jacobson@wayne.edu). Data will be stored in a data warehouse at Wayne State University and transmitted electronically in encrypted form to requestors. Data requestors will need to sign a data access agreement prior to access.

References

 May PA, Gossage JP, Kalberg WO, Robinson LK, Buckley D, Manning M, et al. Prevalence and epidemiologic characteristics of FASD from various research methods with an emphasis on recent in-school studies. Dev Disabil Res Rev 2009;15(3):176–92.

- May PA, Blankenship J, Marais A-S, Gossage JP, Kalberg WO, Barnard R, et al. Approaching the prevalence of the full spectrum of fetal alcohol spectrum disorders in a South African population-based study. Alcohol Clin Exp Res 2013;37(5):818–30.
- Carter RC, Jacobson JL, Molteno CD, Jiang H, Meintjes EM, Jacobson SW, et al. Effects of heavy prenatal alcohol exposure and iron deficiency anemia on child growth and body composition through age 9 years. Alcohol Clin Exp Res 2012;36(11):1973–82.
- Carter RC, Jacobson JL, Sokol RJ, Avison MJ, Jacobson SW. Fetal alcohol-related growth restriction from birth through young adulthood and moderating effects of maternal prepregnancy weight. Alcohol Clin Exp Res 2013;37(3):452–62.
- Day NL, Jasperse D, Richardson G, Robles N, Sambamoorthi U, Taylor P, et al. Prenatal exposure to alcohol: effect on infant growth and morphologic characteristics. Pediatrics 1989;84(3):536–41.
- Day NL, Richardson GA, Geva D, Robles N. Alcohol, marijuana, and tobacco: effects of prenatal exposure on offspring growth and morphology at age six. Alcohol Clin Exp Res 1994;18(4):786–94.
- Day NL, Leech SL, Richardson GA, Cornelius MD, Robles N, Larkby C. Prenatal alcohol exposure predicts continued deficits in offspring size at 14 years of age. Alcohol Clin Exp Res 2002;26(10):1584–91.
- Jacobson JL, Jacobson SW, Sokol RJ, Martier SS, Ager JW, Shankaran S. Effects of alcohol use, smoking, and illicit drug use on fetal growth in black infants. J Pediatr 1994;124(5):757–64.
- Jacobson JL, Jacobson SW, Sokol RJ. Effects of prenatal exposure to alcohol, smoking, and illicit drugs on postpartum somatic growth. Alcohol Clin Exp Res 1994;18(2):317–23.
- Lumeng JC, Cabral HJ, Gannon K, Heeren T, Frank DA. Pre-natal exposures to cocaine and alcohol and physical growth patterns to age 8 years. Neurotoxicol Teratol 2007;29(4):446–57.
- Carter RC, Jacobson JL, Molteno CD, Dodge NC, Meintjes EM, Jacobson SW. Fetal alcohol growth restriction and cognitive impairment. Pediatrics 2016;138(2):e20160775.
- 12. Weinberg J, D'Alquen G, Bezio S. Interactive effects of ethanol intake and maternal nutritional status on skeletal development of fetal rats. Alcohol 1990;7(5):383–8.
- Shankar K, Hidestrand M, Liu X, Xiao R, Skinner CM, Simmen FA, et al. Physiologic and genomic analyses of nutrition-ethanol interactions during gestation: implications for fetal ethanol toxicity. Exp Biol Med 2006;231(8):1379–97.
- Huebner SM, Blohowiak SE, Kling PJ, Smith SM. Prenatal alcohol exposure alters fetal iron distribution and elevates hepatic hepcidin in a rat model of fetal alcohol spectrum disorders. J Nutr 2016;146(6):1180– 8.
- Huebner SM, Helfrich KK, Saini N, Blohowiak SE, Cheng AA, Kling PJ, et al. Dietary iron fortification normalizes fetal hematology, hepcidin, and iron distribution in a rat model of prenatal alcohol exposure. Alcohol Clin Exp Res 2018;42(6):1022–33.
- Saini N, Helfrich KK, Kwan STC, Huebner SM, Abazi J, Flentke GR, et al. Alcohol's dysregulation of maternal-fetal IL-6 and p-STAT3 is a function of maternal iron status. Alcohol Clin Exp Res 2019;43(11):2332–43.
- Carter RC, Jacobson SW, Molteno CD, Jacobson JL. Fetal alcohol exposure, iron-deficiency anemia, and infant growth. Pediatrics 2007;120(3):559–67.
- Carter RC, Georgieff MK, Ennis KM, Dodge NC, Wainwright H, Meintjes EM, et al. Prenatal alcohol-related alterations in maternal, placental, neonatal, and infant iron homeostasis. Am J Clin Nutr 2021;41(12):2114–27.
- Thomas JD, Biane JS, O'Bryan KA, O'Neill TM, Dominguez HD. Choline supplementation following third-trimester-equivalent alcohol exposure attenuates behavioral alterations in rats. Behav Neurosci 2007;121(1):120–30.
- Thomas JD, Garrison M, O'Neill TM. Perinatal choline supplementation attenuates behavioral alterations associated with neonatal alcohol exposure in rats. Neurotoxicol Teratol 2004;26(1):35– 45.
- Thomas JD, La Fiette MH, Quinn VR, Riley EP. Neonatal choline supplementation ameliorates the effects of prenatal alcohol exposure on a discrimination learning task in rats. Neurotoxicol Teratol 2000;22(5):703–11.
- Thomas JD, Tran TD. Choline supplementation mitigates trace, but not delay, eyeblink conditioning deficits in rats exposed to alcohol during development. Hippocampus 2012;22(3):619–30.

- Wagner AF, Hunt PS. Impaired trace fear conditioning following neonatal ethanol: reversal by choline. Behav Neurosci 2006;120(2):482–7.
- 24. Coles CD, Kable JA, Keen CL, Jones KL, Wertelecki W, Granovska IV, et al. Dose and timing of prenatal alcohol exposure and maternal nutritional supplements: developmental effects on 6-month-old infants. Matern Child Health J 2015;19(12):2605–14.
- Wozniak JR, Fink BA, Fuglestad AJ, Eckerle JK, Boys CJ, Sandness KE, et al. Four-year follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder. J Neurodev Disord 2020;12(1):9.
- Warton FL, Molteno CD, Warton CMR, Wintermark P, Lindinger NM, Zollei L, et al. Maternal choline supplementation mitigates alcohol exposure effects on neonatal brain volumes. Alcohol Clin Exp Res 2021; 45(9):1762–74.
- 27. Jacobson SW, Carter RC, Molteno CD, Stanton ME, Herbert JS, Lindinger NM, et al. Efficacy of maternal choline supplementation during pregnancy in mitigating adverse effects of prenatal alcohol exposure on growth and cognitive function: a randomized, doubleblind, placebo-controlled clinical trial. Alcohol Clin Exp Res 2018;42(7):1327–41.
- Jacobson SW, Jacobson JL, Molteno CD, Warton CMR, Wintermark P, Hoyme HE, et al. Heavy prenatal alcohol exposure is related to smaller corpus callosum in newborn MRI scans. Alcohol Clin Exp Res 2017;41(5):965–75.
- Carter RC, Senekal M, Dodge NC, Bechard L, Meintjes EM, Molteno CD, et al. Maternal alcohol use and nutrition during pregnancy: diet and anthropometry. Alcohol Clin Exp Res 2017;41(12):2114–27.
- Jacobson SW, Chiodo LM, Sokol RJ, Jacobson JL. Validity of maternal report of prenatal alcohol, cocaine, and smoking in relation to neurobehavioral outcome. Pediatrics 2002;109(5):815–25.
- Sokol R, Martier S, Ernhart C. Identification of alcohol abuse in the prenatal clinic. In: Chang N, Chao M, editors. Early identification of alcohol abuse. Rockville (MD): Alcohol, Drug Abuse, and Mental Health Administration Research; 1983.
- Carter RC, Wainwright H, Molteno CD, Georgieff MK, Dodge NC, Warton F, et al. Alcohol, methamphetamine, and marijuana exposure have distinct effects on the human placenta. Alcohol Clin Exp Res 2016;40(4):753–64.
- Jacobson SW, Stanton ME, Molteno CD, Burden MJ, Fuller DS, Hoyme HE, et al. Impaired eyeblink conditioning in children with fetal alcohol syndrome. Alcohol Clin Exp Res 2008;32(2):365–72.
- Molteno CD, Jacobson JL, Carter RC, Jacobson SW. Infant symbolic play as an early indicator of fetal alcohol-related deficit. Infancy 2010;15(6):586–607.
- Bearer CF, Jacobson JL, Jacobson SW, Barr D, Croxford J, Molteno CD, et al. Validation of a new biomarker of fetal exposure to alcohol. J Pediatr 2003;143(4):463–9.
- Min MO, Singer LT, Minnes S, Wu M, Bearer CF. Association of fatty acid ethyl esters in meconium and cognitive development during childhood and adolescence. J Pediatr 2015;166(4):1042–7.
- Peterson J, Kirchner HL, Xue W, Minnes S, Singer LT, Bearer CF. Fatty acid ethyl esters in meconium are associated with poorer neurodevelopmental outcomes to two years of age. J Pediatr 2008;152(6):788–92.
- Rasmussen KM, Yaktine AL,editors. Weight gain during pregnancy: reexamining the guidelines. Washington (DC): National Academies Press; 2009.
- 39. Carter RC, Jacobson SW, Booley S, Najaar B, Dodge NC, Bechard LJ, et al. Development and validation of a quantitative choline food frequency questionnaire for use with drinking and non-drinking pregnant women in Cape Town, South Africa. Nutr J 2018;17(1):108.
- Dodd KW, Guenther PM, Freedman LS, Subar AF, Kipnis V, Midthune D, et al. Statistical methods for estimating usual intake of nutrients and foods: a review of the theory. J Am Diet Assoc 2006;106(10):1640–50.
- Henry CJK. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr 2005;8(7a):1133– 52.

- 42. Prentice AM, Poppitt SD, Goldberg GR, Murgatroyd PR, Black AE, Coward WA. Energy balance in pregnancy and lactation.In: Lonnerdal B,editor. Nutrient regulation during pregnancy, lactation, and infant growth. New York: Plenum Press; 1994. p. 11–26.
- de Onis M, Garza C, Victora CG, Onyango AW, Frongillo EA, Martines J. The WHO Multicentre Growth Reference Study: planning, study design, and methodology. Food Nutr Bull 2004;25(1 Suppl 1):S15–26.
- 44. Jacobson SW, Carter RC, Molteno CD, Meintjes EM, Senekal MS, Lindinger NM, et al. Feasibility and acceptability of maternal choline supplementation in heavy drinking pregnant women: a randomized, double-blind, placebo-controlled clinical trial. Alcohol Clin Exp Res 2018;42(7):1315–26.
- McClelland GH, Judd CM. Statistical difficulties of detecting interactions and moderator effects. Psychol Bull 1993;114(2):376–90.
- Hollingshead AB. Four factor index of social status. Yale J Sociol 2011;8:21–51.
- Lands WE. A review of alcohol clearance in humans. Alcohol 1998;15(2):147–60.
- Ramchandani VA, Kwo PY, Li TK. Effect of food and food composition on alcohol elimination rates in healthy men and women. J Clin Pharmacol 2001;41(12):1345–50.
- Kable JA, Coles CD, Keen CL, Uriu-Adams JY, Jones KL, Yevtushok L, et al. The impact of micronutrient supplementation in alcoholexposed pregnancies on information processing skills in Ukrainian infants. Alcohol 2015;49(7):647–56.
- Jacobson SW, Stanton ME, Dodge NC, Pienaar M, Fuller DS, Molteno CD, et al. Impaired delay and trace eyeblink conditioning in schoolage children with fetal alcohol syndrome. Alcohol Clin Exp Res 2011;35(2):250–64.
- Algarín C, Peirano P, Garrido M, Pizarro F, Lozoff B. Iron deficiency anemia in infancy: long-lasting effects on auditory and visual system functioning. Pediatr Res 2003;53(2):217–23.
- McEchron MD, Alexander DN, Gilmartin MR, Paronish MD. Perinatal nutritional iron deficiency impairs hippocampus-dependent trace eyeblink conditioning in rats. Dev Neurosci 2008;30(4):243–54.
- 53. Otero NKH, Thomas JD, Saski CA, Xia X, Kelly SJ. Choline supplementation and DNA methylation in the hippocampus and prefrontal cortex of rats exposed to alcohol during development. Alcohol Clin Exp Res 2012;36(10):1701–9.
- 54. Bekdash RA, Zhang C, Sarkar DK. Gestational choline supplementation normalized fetal alcohol-induced alterations in histone modifications, DNA methylation, and proopiomelanocortin (POMC) gene expression in β-endorphin-producing POMC neurons of the hypothalamus. Alcohol Clin Exp Res 2013;37(7):1133–42.
- 55. Edwards AE, Senekal M, Dodge NC, Meintjes EM, Molteno CD, Jacobson JL, et al. Fetal alcohol growth restriction is not attributable to infant feeding practices in a prospective birth cohort in Cape Town. Curr Dev Nutr 2021;5(Suppl 2):739.
- Jensen H, Batres-Marquez S, Carriquiry A, Schalinske K. Choline in the diets of the U.S. population: NHANES, 2003–2004. FASEB J 2007;21:6, 219.
- 57. Lewis ED, Subhan FB, Bell RC, McCargar LJ, Curtis JM, Jacobs RL, et al. Estimation of choline intake from 24 h dietary intake recalls and contribution of egg and milk consumption to intake among pregnant and lactating women in Alberta. Br J Nutr 2014;112(1):112–21.
- Bailey RL, Pac SG, Fulgoni VL, Reidy KC, Catalano PM. Estimation of total usual dietary intakes of pregnant women in the United States. JAMA Netw Open 2019;2(6):e195967.
- Insitute of Medicine. Choline. In: Dietary reference intakes for folate, thiamin, riboflavin, niacin, vitamin B12, panthothenic acid, biotin, and choline. Washington (DC): National Academies Press; 2006.
- Institute of Medicine. Iron. In: Dietary reference intakes. Washington (DC): National Academies Press; 2006.
- Oken E, Kleinman KP, Rich-Edwards J. A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr 2003;3(6):1–10.
- Watson PF, Petrie A. Method agreement analysis: a review of correct methodology. Theriogenology 2010;73(9):1167–79.